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ABSTRACT 
 
 
Infections are frequently associated with changes in glucose level, either hyperglycemia or 
hypoglycemia. The factors that influence glucose change and/or the mechanism(s) that result 
in altered glucose level during infection are not determined.  Therefore, the purpose of this 
study was to investigate the role of infection-induced changes in IL-6 on blood glucose level. 
Blood glucose and insulin level were measured in Balb/c mice infected with influenza virus 
A/PR/8/34 at a dose of 50 ul containing 512 HAU or 1024 HAU (high dose).   In addition, 
anti-IL-6 neutralizing antibody was used to determine the extent to which IL-6 may influence 
infection-associated changes in glucose or insulin.  We found an increase in serum IL-6 at 
days 1, 2, 3, 5, and 6 post-infection and a significant decline in blood glucose at days 5 and 6 
post-infection that was more pronounced with a higher dose of virus.   Insulin level increased 
significantly on day 1 post-infection and then decreased on days 3, 4, and 5 post-infection 
when a higher dose of virus was used. With the administration of IL-6 neutralizing antibody, 
there was an attenuation of the decline in glucose level at day 5 post infection, suggesting a 
potential role for IL-6 in mediating blood glucose during infection.  With respect to insulin, 
the mice treated with IL-6 neutralizing antibody had greater insulin levels than infected mice 
treated with irrelevant antibody at day 2 post-infection.  However at day 5 post-infection, the 
decline in insulin was not prevented by IL-6 neutralizing antibody suggesting that IL-6 may 
mediate insulin response at only specific time points during infection.  Taken together, the 
results demonstrate that insulin and glucose levels are altered by infection, and that IL-6 may 
play a role in mediating these responses.  The actual mechanisms by which IL-6 is involved 
remain to be determined.  
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INTRODUCTION 
 
Alteration in Blood Glucose Level 
Multiple factors contribute to the regulation of blood glucose, however there are 
several conditions such as stress, infection, or myocardial infarction in which blood glucose 
levels may be temporarily altered. Chronic elevations of blood glucose occur in individuals 
with diabetes (a disease that affects 2-4% of the U.S. population) (Thomas et al., 1993).  
According to WHO, the diagnostic criteria of diabetes is characterized by fasting blood 
glucose level >140mg/dl. This high blood glucose level is due to either deficiency of the 
circulating insulin or increase in insulin resistance with the end result of inadequate action of 
insulin on different body tissues and elevation of blood glucose level.  It is important to note 
that conditions in which blood glucose may be altered temporarily (i.e., infection) may 
further exacerbate the chronically elevated blood glucose levels in the diabetic).  Other 
examples of temporary conditions that may cause acute hyperglycemia in diabetic or non 
diabetics include stroke, thermal injury, and acute infection (Thomas et al., 1993; Heismayr 
et al., 2006; Norhammar et al., 2002; Holm et al., 2004). The acute elevation in glucose level 
and hyperglycemia may be associated with severe and life threatening complications such as 
rapid mental deterioration, coma and death (Thomas et al., 1993).  It has also been observed 
that mortality rates are greater in patients presenting with hyperglycemia upon admission to 
intensive care units (Whitcomb et al., 2005).  For these reasons, a better understanding of the 
mechanism(s) by which certain conditions such as infection result in hyperglycemia is very 
important.  With an understanding of the mechanisms, it may be possible to develop an 
appropriate intervention. 
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REVIEW OF LITERATURE 
 
Acute Infection Promotes Changes in Blood Glucose Level 
In addition to an increased incidence and susceptibility to infection in patients with 
high glucose levels (Segado et al., 1999), acute infections are associated with alteration in 
blood glucose level.  For example, bacterial infections such as Cholera or tuberculosis may 
result in hyperglycemia.  As infection is cleared, and/or after antibiotics are administered, the 
high glucose levels may return to normal (Ronan et al., 1997; Jaward et al., 1995).  Viral 
infection is also correlated with hyperglycemia. For example, severe acute respiratory 
syndrome (SARS) has been associated with elevated fasting plasma glucose in both diabetics 
and non diabetic patients.  Those with more severe disease as assessed by SaO2 measures, 
tended to show greater elevations in fasting plasma glucose (Yang et al., 2006).  Studies in 
mice similarly show hyperglycemia during viral infection.  For example, mice infected with 
coxsackieB virus developed hyperglycemia 8 weeks later. Reexposure to coxsackieB virus 
increased the frequency and onset of hyperglycemia in the infected mice (Horwitz et al., 
2003).  Also it has been demonstrated that insulin resistance occurs during infection and may 
persist for 1-3 months post-infection.  One study evaluated insulin resistance during and 
following acute viral or bacterial infection in young adults (mean age 29). The degree of 
insulin resistance observed in these younger adults was equivalent to that predicted for an 84 
year old normal person or an age-matched obese individual with a body mass index  (BMI) = 
37 kg/m2 (Yki-Jarvinen et al., 1989).  In addition, other studies showed that up to 40% of 
acute hyperglycemia and development of ketoacidosis in diabetic patients are precipitated by 
infection, particularly respiratory and urinary tract infections (Thomas et al., 1993; Segado et 
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al., 1999).  Based on the important association between infections and elevation of blood 
glucose level, it has been suggested that continuous monitoring of blood glucose data in 
diabetic patients may have the potential to predict outbreaks of infectious diseases (Arsand et 
al., 2005). 
Infection has also been reported to decrease blood glucose level leading to 
development of hypoglycemia, although it appears that the timing of blood glucose 
assessment in relation to stage of infection may be important.  It has been shown that 
lipopolysaccaride (LPS) (a component of gram negative bacteria) decreased blood glucose 
level 4-6 hrs following intraperitoneal injection in BALB/c mice, and that decline was 
dependent on the dose of LPS (Oguri et al., 2002).  It is possible that the type of the pathogen 
is important in determining whether hypoglycemia or hyperglycemia will occur. Moreover, 
the timing of blood glucose measurement in relation to pathogen challenge may play a 
critical role in determining the type of glucose alteration.  For example, some evidence 
suggests that severe bacterial infection and sepsis may result in acute hyperglycemia due to 
increase in proinflammatory cytokines. The elevated proinflammatory cytokines may then 
cause insulin resistance, followed by a hyper-metabolic state with increased glucose 
consumption, glycogen depletion and gluconeogenesis inhibition eventually leading to the 
development of hypoglycemia (Yu et al., 2003; Andersen et al., 2004; Miller et al., 1980).  In 
vibrio-cholera, hyperglycemia was noticed in the first few hours of diarrhea and that was 
corrected after electrolyte replacement. The hyperglycemia could be due to the elevation of 
diabetogenic hormones e.g. norepinephrine, glucagons and corticosteroid in response to 
stress produced by this type of infection (Ronan et al., 1997).  The above are possible 
mechanisms that have been associated with alteration in glucose metabolism in certain types 
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of pathogens.  Until the mechanism by which infection may alter blood glucose is elucidated, 
it will be difficult to predict which types of infection may alter glucose, and at what time 
point during the infection are blood glucose levels most likely to change. 
 
Infection and Chronic Elevation of Blood Sugar Level 
There is evidence from multiple studies to suggest that infections cause acute 
alteration in blood glucose level.  In addition, certain viruses that may cause chronic disease 
may also predispose the individual to persistent elevation of blood glucose level, leading to 
the development of diabetes mellitus.  Some evidence suggests that hepatitis C virus (HCV) 
could impair glucose tolerance and approximately 43.2% of HCV-infected patients became 
diabetic later in their lives (Kwon et al., 2005). Another study showed that diabetes occurs 
more frequently in HCV-seropositive than HCV-seronegative beta-thalassamia patients 
(Mowla et al., 2004).  In addition to HCV virus, human immunodeficiency virus (HIV) 
infection is also associated with blood glucose elevation.  It is found that HIV-patients 
treated with antiretroviral agent (HAART) are more likely to develop fat redistribution or 
lipodystrophy. These lipodystrophic-HIV infected patients exhibit glucose tolerance 
impairment and developed diabetes mellitus more often than non-lipodystrophic HIV- treated 
patients (Haugaard et al., 2005).  Moreover, in renal transplant patients, asymptomatic 
cytomegalovirus (CMV) infection was associated with increased incidence of new-onset 
diabetes mellitus and impairment of insulin release (Hjelmesaeth et al., 2004).  Case studies 
also exist in the literature documenting the development of Type 1 diabetes following a flu-
like illness (Wasmuth et al., 2000).  In general, numerous studies have shown an associated 
between prior virus infection and subsequent development of Type I diabetes as recently 
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reviewed (Jaeckel et al., 2002).  In addition to chronic viral infections, chronic bacterial 
infections have also been associated with altered glucose.  For example, helicobacter felis 
infection increased glycosylated hemoglobin HbA1c and mortality rate in streptozotocin-
induced diabetic mice (Spinetti et al., 2005). Therefore, the results of numerous studies 
suggest that infection (acute or chronic) are situations in which blood glucose may be altered 
temporarily and potentially may lead to long-term alterations. 
 
Influenza Virus Infection in Mice or Humans and Blood Glucose 
The severity of influenza infection appears to be greater in diabetics.  For example, the 
number of hospitalization of diabetic patients due to ketoacidosis and pneumonia was 
increased in epidemic from non-epidemics years (P < 0.01 and P < 0.01 respectively).  The 
mortality rate among diabetic patients was increased, with the estimated relative risk of death 
in diabetic patients equal to 91.8 during epidemic years compared to 30.9 in non-epidemic 
years (Bouter et al., 1991; Diepersloot et al., 1990). The increased rates of morbidity and 
mortality among diabetic patients during influenza epidemic could be due to the effect of 
influenza virus-induced immune mediated effects on blood glucose, and/or may be due to 
hyperglycemia-associated changes of innate immune response.  Some evidence in support of 
the latter possibility has been published, yet to our knowledge, it has not been determined 
how immune response to influenza infection may impact blood glucose.  With respect to 
hyperglycemia-associated changes of innate immunity, it was found that hyperglycemia 
inhibits glucose 6 phosphate dehyrogenase G6PD and impairs phagocyte NADPH oxidase 
activity, leading to inhibition of the antimicrobial function of the polynuclear neutrophils 
(Moutschen et al., 2005; Engelich et al., 2001).  Influenza infection may result in a secondary 
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bacterial infection, via compromised anti-bacterial innate defenses and may increase the 
likelihood of developing a secondary infection.  Influenza virus infection has been shown to 
decrease neutrophil function either through interaction of viral hemagglutinin to sialylated 
neutrophil surface molecules or via acceleration of monocyte and neutrophil apoptosis 
(Engelich et al., 2001).  The depression in monocyte and neutrophil function (due to 
hyperglycemia and/or via actions of the influenza virus) may increase susceptibility to 
bacterial infections, thereby resulting in elevated hospitalization rates and mortality in 
diabetic patients during influenza pandemic. 
Also, in experimental studies, it has been found that diabetic mice are more susceptible 
to influenza virus infection than non-diabetic mice (Reading et al., 1998).  In this study, viral 
load in lung tissues was higher in mice with elevated blood glucose levels at the time of 
infection.  A 10-fold difference in virus yield was observed as early as 24 hours post-
infection in diabetic mice compared to non diabetic mice.  This enhanced susceptibility of 
influenza infection in diabetic mice was thought to be due in part to impairment of collectin-
mediated host defense of the lung by glucose.  Consequently, the neutralization of influenza 
virus particles by surfactant binding lectins was abolished. Therefore, evidence in humans 
and animal models suggests that elevated blood glucose could increase the incidence and 
severity of influenza infection. 
Fewer studies were documented explaining the association between influenza virus and 
hypoglycemia. In experimental studies, intravenous inoculation of mice with influenza B/Lee 
virus impaired gluconeogenesis in the liver and led to the development of severe 
hypoglycemia. In this study blood glucose level felt down at 6 hrs and persists up to 30hrs 
later (Davis et al., 1993).  Also, laboratory finding of influenza associated encephalitis 
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patients infected with influenza A and B virus revealed glucose level < 60mg/dl (Tsuneo et 
al., 2002).  Taken together, evidence showed that influenza infection may be associated with 
either hyperglycemia or hypoglycemia. The alteration in glucose level may be depending on 
virus strain, severity of infection or could be related to timing of glucose measuring during 
infection. 
 
Pathogenesis of Influenza Virus 
Influenza virus is highly antigenic; it is a single strand RNA with an outer lipoprotein 
envelope. The envelope is covered by 2 different spikes, hemagglutinin and neuraminidase. 
Influenza virus is characterized by high molecular recombination of the genome RNA 
(antigenic shifts) that determines the type of hemagglutinin and neuraminidase proteins.  A 
significant change in the type of hemagglutinin and neuraminidase protein may result in an in 
epidemic, and also may influence the pathogenesis of the disease (Enserink et al., 2004; Li et 
al., 2004).  For example, H1N1 (Spanish flu) was the dominant strain during 1918 epidemic 
year. However H2N2 (Asian flu), H3N2 (Hong Kong flu), and H5N1 (avian flu) were the 
common type during the years 1957, 1968 and 1997 respectively and each of these major 
changes in hemagglutinin or neurominidase resulted in pandemics (Enserink et al., 2004; Li 
et al., 2004).  Also, influenza virus antigenicity is dependent on minor gene mutation 
(antigenic drifts).  Antigenic drift describes the minor changes that generally occur annually 
in either the hemagglutinin or the neuraminidase or in both.  In contrast, major antigenic shift 
occurs infrequently and describes the appearance of viral strains with surface antigens that 
are only distantly related to those on previous strains.  Antigenic shift may involve the 
hemagglutinin alone, or the neuraminidase as well.  It is generally thought that minor 
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antigenic variations are due to mutations in hemagglutinin and/or neuraminidase genes 
whereas major antigenic shift may occur as a result of gene reassortment between a human 
and an animal strain.  Major antigenic shift typically results in influenza epidemics or 
pandemics (Warren et al., 1994). 
It has been suggested that the pathogenesis of influenza infection may be related to the 
associated inflammatory mediators that occur during infection.  In vitro studies using 
alveolar macrophages demonstrated that influenza A virus infection resulted in increased IL-
1β, IL-6, IL-8, and TNF-α (Seo et al., 2004).  Recent studies with the influenza H5N1 virus 
which resulted in high mortality rates showed that gene transcription of the pro-inflammatory 
cytokine TNF-α in the infected human primary monocyte-derived macrophages was 
markedly elevated (Cheung et al., 2002).  Also, human alveolar and bronchial epithelial cells 
infected with H5N1 virus produce higher level of IL-6 and interferon-β as compared to the 
H1N1 virus (Chan et al., 2005).   Experiments using in vivo models have shown similar 
results.  For example, alveolar macrophage isolated from pigs infected with H1N1 or H3N2 
influenza virus produced high level of IL-6 and TNF-α cytokines (Seo et al., 2004).  Also, in 
H1N1 infected mice, IL-6, TNF α and Type I IFNs in bronchoalvealar fluid (BAL) were 
elevated (Conn et al., 1995). Experiments using influenza virus NS gene reassortants in mice 
demonstrated that reassortants containing the H5N1 gene resulted in increased pulmonary 
concentrations of the inflammatory cytokines IL-1α, IL-1β, IL-6, and chemokine KC, similar 
to the findings obtained from humans who died from influenza H5N1 (Lipatov et al., 2005).  
The result from other studies suggests that high serum levels of IL-6, TNF-alpha and soluble 
TNF receptor 1 sTNFr1 observed during influenza infection was associated with encephalitis 
(Tsuneo et al., 2002).  Taken together, there is evidence from in vitro models demonstrating 
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that influenza-infected cells may produce inflammatory cytokines, and findings from in vivo 
studies suggest that elevated pro-inflammatory cytokines contribute to severity of infection. 
 
Effect of IL-1α, IL-1β, and IL-2 on Blood Glucose  
Pro-inflammatory cytokines appear to be a critical factor in glucose homeostasis.  
Previous studies indicate that cytokines may act as hormones and alter blood glucose level. 
IL-1 has been identified as the major mediator of hypoglycemia during septic shock in a mice 
experiment (Oguri et al., 2002). The intra-peritoneal injection of low dose of IL-1 alpha and 
IL-1 beta (0.1ug/kg mice body weight) were found to be capable of the reducing blood 
glucose level (Oguri et al., 2002; Endo et al., 1991). This reduction in blood glucose level 
was due to increased tissue glucose uptake and inhibition of gluconeogenesis. Similarly, it 
was found that glucose-6-phosphatase and phosphoenolpyruvate carboxykinase (the key 
enzymes in gluconeogenesis) were decreased in mice bearing IL-1-beta secreting tumor 
compared to mice injected with non secreting tumor cells (Metzger et al., 2004).  In human 
studies, it has also been observed that alteration of blood glucose level could be induced by 
cytokines.  Subcutaneous administration of IL-2 produced hypoglycemia (Harnish et al., 
2005). Although direct administration of IL-1 and/or IL-2 appear to result in hypoglycemia, 
it is less clear whether infection-induced changes in IL-1α, IL-1β, or IL-2 contribute to 
altered blood glucose. 
 
Effect of IL-6 on Glucose Homeostasis and Insulin Sensitivity 
It has been shown that IL-6 may be produced by multiple cells including adipocytes, 
endothelial cells, hepatocytes, as well as cells of the immune system.  In contrast to the 
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hypoglycemia observed after IL-1 or IL-2 injection, the subcutaneous injection of IL-6 
increased blood glucose level in humans in a dose dependent manner (Harnish et al., 2005; 
Tsigos et al., 1997).  Direct infusion of bacterial LPS in humans resulted in increased glucose 
(6-8%) and increased plasma insulin (19-38%) at 24 hours after infusion (Andersen et al., 
2007).   Plasma IL-6 and TNF showed greater than a 100 fold increase in concentration 
which reached a peak 2 hours after LPS infusion (but preceded the change in glucose and 
insulin).  Also, LPS and TNF expression in adipocytes and monocytes peaked 2-4 hours after 
infusion.  The findings from this study suggested that cytokines precede blood glucose and 
insulin changes in response to bacterial LPS.   
IL-6 has been associated with insulin resistance.  In humans, the hyperinsulinemic-
euglycemic clamp was used to test insulin sensitivity, and it was demonstrated that plasma 
IL-6 levels were inversely correlated with insulin sensitivity (Heliovaara et al., 2005).  
Similarly in a mouse model, using the hyperinsulinemic-euglycemic clamp, it was observed 
that acute IL-6 administration decreased insulin-stimulated glucose uptake in muscle, which 
contributed significantly to the change in whole-body insulin resistance.  Furthermore, these 
investigators demonstrated that this effect was associated with defects of the insulin-
stimulated IRS-1-associated PI 3-kinase in muscle (Hypo-Jeong et al., 2004).  In addition, in 
this same study, it was found that IL-6 administration increased tyrosine phosphorylation of 
STAT3 in skeletal muscle, and it is known that IL-6 binding results in recruitment of the 
signal transducing molecule STAT3 leading to the activation of suppressor of cytokine 
signaling (SOCS)-3.  SOCS-3 has been shown to inhibit insulin signaling in hepatocytes and 
adipocytes (Emanuelli et al., 2000; Emanuelli et al., 2001).  Other in vivo studies have 
demonstrated that adipose tissue IL-6 content is correlated with resistance to insulin 
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activation of glucose uptake (Bastard et al., 2002) and chronic exposure to IL-6 also causes 
hepatic insulin resistance in mice (Klover et al., 2003).  Studies performed in vitro have 
shown that IL-6 inhibits insulin signaling and insulin action in isolated mice hepatocytes and 
in hepatoma cell lines via a decrease in tyrosine phosphorylation of insulin receptor 1 (IRS1) 
and protein kinase activation (Senn et al., 2002). Also, IL-6 impaired insulin signaling in 
3T3-L1 subcutaneous adipose cells isolated from humans (Rotter et al., 2003).  Therefore, a 
substantial number of studies have suggested that IL-6 may promote insulin resistance, 
although this final has not been entirely consistent.  Other experimental studies in vivo 
demonstrated that acute infusion of IL-6 for 120 min with hyperinsulinaemic- euglycemic 
clamp in rats did not alter the effect of insulin on whole body glucose uptake (Sopasakis et al. 
2004). Other researchers indicate that infusion of IL-6 in type 2 diabetic patients and aged 
matched control subjects does not impair or enhance glucose uptake and glucose level remain 
at the same level all the time (Peterson et al., 2004).  In addition other investigators 
demonstrated that IL-6 may be associated with increase insulin sensitivity and enhancement 
in glucose uptake.  For example, in vitro studies 3T3-L1 adipocytes treated with recombinant 
murine IL-6 for 5 hrs increased glucose transport by 20% (Stouthard et al., 1996).  Also there 
was a high basal glucose level and impairment in response to the glucose tolerance test in IL-
6 deficient mice (Wallennius et al., 2002). Also it has been shown that IL-6 increased glucose 
disposal during hyperinsulinemic-euglycemic clamp in healthy humans (Carey et al., 2006).  
Therefore, data with respect to the role of IL-6 role on insulin sensitivity is controversial. 
Figure 1 demonstrates a hypothesized role of IL-6 as a mediator of insulin sensitivity within 
insulin responsive cells (IR) (Carey et al., 2004). This figure demonstrates that IL-6 may act 
in a manner similar to insulin and result in phosphorylation of tyrosine residue of IRS-1.  
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IRS-1 phosphorylation will lead to PI3K activation and enhance insulin action. However in 
chronic elevation of IL-6, Akt phosphorylation can lead to phosphorylation of serine instead 
of tyrosine residue on IRS-1 via activation of the mammalian target of rapamycin (mTOR). 
This leads to impaired insulin signaling and increased insulin resistance. In addition, IL-6 
may activate suppressors of cytokine signaling through Jak/Stat pathway to inhibit tyrosine 
phosphorylation of IRS-1. This also will inhibit insulin action.  Therefore, IL-6 may increase 
or decrease insulin action and glucose uptake. However whether IL-6 is a main mediator of 
glucoses homeostasis during infection is not clear.   
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HYPOTHESIS 
 
We hypothesize that influenza-associated systemic increase of the pro-inflammatory 
cytokine IL-6, results in altered blood glucose and insulin (and/or tissue response to insulin). 
This hypothesis was tested by administering anti-IL-6 antibody prior to and during infection 
to determine whether the antibody blocks infection-induced changes in blood glucose and 
insulin levels. 
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MATERIAL AND METHODS 
 
Animals  
8-12 week-old Balb/c mice were obtained from the Jackson Laboratory. The animals 
were maintained in the animal facility at Iowa State University. Each mouse was housed in a 
separate cage at room temperature and kept on 12 h dark-light cycle starting at 0600. Mice 
were fed the standard rodent chow and water (except at days in which fasting glucose was 
measured). The university animal care committee (COAC) approved all protocols used on 
animals.  
 
Influenza Virus Infection and Collection of Blood for Assessment of Glucose, Insulin 
and IL-6  
Mice were infected by intranasal inoculation of influenza virus under light anesthesia 
with CO2.  Different doses of the mouse adapted influenza virus (H1N1- A/PR/8/34) were 
tested in mice.  The virus was grown in chicken embryo obtained at the Veterinary 
Diagnostic Laboratory at Iowa State University.   In preliminary experiments several doses of 
virus were tested ranging from 25 μl of a virus with a titer equal to 12.5 hemagglutination 
units (HAU) up to a dose of 50 μl at a titer equal to 512 HAU.  Based on the preliminary 
data, a dose of 50 μl at HAU=512 was the minimum dose in which an effect on blood 
glucose was observed.  Subsequent experiments used 50 μl at either 512 HAU or 1024 HAU.  
Control mice were similarly anesthetized and inoculated with 50 μl of saline solution 0.9% 
NaCl.             
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In one set of experiments, blood glucose was measured prior to influenza infection, 
and post-infection at times points ranging from day 1 post-infection to day 6 post-infection.  
At the lower dose of virus test (50 μl of 512 HAU), 20 mice were infected with virus, and on 
days 1, 2, 3, 4, and 5 post-infection, 4 mice were euthanized (4 mice per day) and glucose 
was measured.  In addition, glucose was measured in 4 non-infected mice as a control 
comparison for day to day variability in blood glucose.  At a higher dose of virus, (50 μl of 
1024 HAU), 8 mice were infected and blood glucose was measured at the following time 
points, 24 hr pre-infection, and days 1, 3, and 5 post-infection.  A separate group of 8 mice 
were also infected and blood glucose was measured at the following time points, 24 hr pre-
infection, and on days 2, 4, 6, post-infection.  Again, a control group of non-infected mice 
was measured as a comparison for day to day variability in blood glucose.  Body weight, 
food and water intake were measured in the same mice used to assess blood glucose at 
multiple time points post-infection in order to establish change over time in body weight and 
food/water intake. 
A second set of experiments was used to assess insulin levels and serum IL-6.  With a 
virus dose equal to 50 μl of 512 HAU, 20 mice were infected and 4 mice were euthanized at 
each of the following time points post-infection (day 1, 2, 3, 4, and 5).  Non-infected mice 
(n=4) were used as a control comparison.  At a higher dose of virus (50 μl of 1024 HAU), 30 
mice were infected, and serum IL-6 and insulin were measured at the following time points 
post-infection (day 1, 2, 3, 4, 5, and 9).  Two of the mice to be measured at day 9 post-
infection died before day 9 and therefore at day 9, there were only 3 infected mice.  Again, 
non-infected mice (n=5) were used as a control comparison.   
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Sampling of Blood and Broncho-Alveolar Fluid for Cytokine and Hormone Assays 
Mice were euthanized by carbon dioxide before collection of broncho-alveolar fluid 
(BAL) and blood. Blood was drawn by cardiac puncture into a 1cc syringe with a 27 ½  
gauge needle.  Blood was stored at room temperature for 30 min.  The blood was centrifuged 
at 2000rpm for 30 min. The serum was collected and stored at -200C for until further 
analysis.  
 For BAL: Lungs were lavaged with 1ml sterile AIM-V media through a small 
catheter inserted into the trachea. Lungs were washed twice, and the broncho-alveolar fluid 
was collected and centrifuged for 15min at 1500rpm to remove cells and debris. The 
supernatant was stored at -200C until assayed for IL-6.  
 
Determination of Blood Glucose   
In order to minimize stress that could produce an increase in blood glucose, mice 
were acclimated to the protocol for 7-10 days prior to actual glucose level measurement. 
Mice were placed in a 50 ml centrifuge tube with an opening hole at the cover, the right leg 
was shaved, and the saphenous vein was exposed.  In order to obtain fasting blood glucose, 
food was taken away and mice were left to fast for 4-8 hrs with access only to water.  The 
optimum level was detected after 6 of fasting and the blood glucose range between 80-120 
mg/dL. Mice were divided into groups and fasted for 6-7 hrs. The blood taken from the 
saphenous vein was directly applied to a strip and glucose was determined with Accu-Check 
Advantage glucometer.  Several experiments were done to determine differences between 
infected and non infected mice groups and also to detect the time course for changes in 
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glucose level.  The time points and doses used were described above under “Influenza virus 
infection and collection of blood for assessment of glucose, insulin and IL-6”   
 
Measurement of Body Weight and Food and Water Intake 
Before infection mice were weighed on a top loading balance, and food and water in 
each cage were weighed on the same scale. Daily measurement was performed prior to 
infection and for five days post-infection. The total amount of food was subtracted from the 
total amount of food on the previous day to determine the actual amount of food consumed 
each day during infection. Water intake was assessed with the same method. Body weight, 
food intake and water intake were also measured in non-infected mice.  
 
Enzyme-Linked Immunoassay ELISA for IL-6 Cytokine Measurement 
IL-6 was measured by ELISA (BD Biosciences, San Diego, CA lot # MF 26406) with 
test sensitivity > 4pg/ml.  For this ELISA kit, the intra-assay % CV = 6.4 and the inter-assay 
% CV = 6.5. The plate was coated with 100ul/well capture antibodies diluted at 1: 250 in a 
coating buffer 0.1 M sodium carbonate, pH 9.5 freshly prepared (8.40g NaHCo3, 3.56g 
Na2Co3;q.s. to 1.0 L; pH to 9.5). The plate was sealed and kept overnight at 40C. Wells were 
washed and blocked with 200 μl of assay diluent at room temperature for an hour. After 
several wash steps with PBS buffer, 100 μl of standard and samples were added to each well, 
and the plate was sealed and incubated for 2hrs. Several washes with PBS buffer were 
performed.  Then, the working detector solution containing strepatavidin-HRP-conjugated 
and biotinylated anti-mouse IL-6 monoclonal antibody was prepared. 40 μl of strepatavidin-
HRP-conjugated and 40 μl of the detection antibody were added to 10ml of assay diluent. 
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The fraction of the IL-6 bound to the enzyme conjugate was detected by reaction with 
100μl/well of tetramethybenzidine and hydrogen peroxide solution. The colorimetric 
produced by the reaction was assessed by reading the optical density at 655nm using a BIO-
RAD micro-plate reader.  
 
Measurement of Insulin Level  
Insulin level was measured by enzyme-linked immunosorbent assay kit (Mercodia 
Mouse Insulin ELISA, ALPCO diagnostics).The sensitivity of the assay was 0.10μg/l. For 
this ELISA kit, CV% within the assay = 2.2 and the CV % between the assay = 4.9. Twenty-
five μl of samples and calibrators and 25 μl of peroxidase-conjugated anti-insulin antibodies 
were added into anti-insulin antibodies coated micro-titration wells. The plate was incubated 
on a shaker for 2 hrs at room temperature. Several washing steps were performed to remove 
unbound enzyme labeled anti-insulin antibodies. The bound conjugate was detected by 
reaction with tetramethylbenzidine at 200 μl/well. The reaction was stopped by adding 
sulfuric acid H2SO4 in the stop solution. The absorbance was read at 450 nm by 
spectrophotometer and compared with the calibrators.  
 
Treatment of Mice with anti-IL-6 Antibody  
In initial experiments, the dose of antibody tested was based on published literature.  
MP5-20F3 anti-IL-6 antibody was purchased from BD Pharmingen.  Mice were injected 
through an intra-peritoneal (i.p.) route with 100 μg/100 μl of anti-IL-6 mAB. Control mice 
were similarly injected i.p. with 100 μl saline.  Mice were injected with antibody at 4 hours 
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prior to infection. At days 24 and 48 hours post-infection serum was collected and IL-6 was 
measured.  Prior administration of the anti-IL-6 antibody significantly blocked the infection 
associated increase in IL-6 at day 1 post-infection and tended to block to increase at day 2 
post-infection (Fig. 2) (although serum IL-6 did not increase to the same extent at day 2 post-
infection compared to day 1 post-infection based on our previous data).  The dose of 100 μg 
was used in subsequent experiments.              
 
Administration of Anti-IL-6 Antibody in Vivo and Assessment of Blood Glucose Post-
Infection 
Mice were injected through an intra-peritoneal (i.p.) route with 100 μg in a 100 μl 
volume of saline of anti-IL-6 mAb, clone MP5-20F3 (Anti-IL-6 antibody treatment group) 
Control mice were similarly injected i.p. with 100 μg rat IG1 κ  purchased also from BD 
Pharmingen (Control antibody treatment group).  Injections were performed 4 hrs before 
infection and then daily for four days during infection.  A non-infected mice group was 
similarly injected with 100μl saline at the corresponding times.  In the first set of 
experiments five mice per treatment group were used, and blood glucose was measured 
before infection and again at day 3 (72 hrs) and day 5 (120 hrs) post infection.   At the time 
of euthanization on day 5, insulin was also measured.  In the second set of experiments, the 
same three treatment groups were used.  On day 1 (24hr) post-infection, 5 mice per treatment 
group were euthanized and serum IL-6 and insulin were measured.  On day 2 (48 hr) post-
infection, again 5 mice per treatment group were euthanized and blood was collected for 
assessment of IL-6 and insulin.  
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Data Analysis 
Statistical analysis of the data was performed using SPSS. In experiments in which 
IL-6, glucose, or insulin was measured once per mouse, a one way ANOVA was used to 
compare means from more than two groups.  Post hoc tests were used with LSD as the post-
hoc test to establish which treatment groups differed.  In the experiments in which glucose 
was measured at more than one time point in the same mouse, a mixed ANOVA was used 
(treatment by time).  If a significant treatment by time interaction was found, appropriate 
one-way ANOVA’s were performed to establish differences between groups at given time 
points.  
 
Series of the Experiments  
In initial experiments, different doses of virus were tested (ranging from 25 μl of 12.5 
HAU/0.025 ml to 50 μl of 512 HAU/0.05ml) to determine the extent to which a different 
virus dose might affect IL-6, glucose, and insulin levels.  At lower levels of virus, blood 
glucose and insulin responses were variable and did not show large fold changes.   It was 
concluded that higher doses of virus should be tested to determine whether the higher doses 
would have a greater effect. 
In the second set of experiments, two higher doses of virus (50 μl of 512 HAU/0.05 
ml and 1024 HAU/0.05 ml) were used to determine the effect of infection on the pattern of 
changes on IL-6, glucose and insulin levels one week after infection. Body weight and food 
intake were also measured. Significant effects of infection on blood glucose, insulin, body 
weight and IL-6 were observed with the highest dose of virus.  The next experiments sought 
to determine whether anti-IL-6 antibody administered in vivo could block the infection-
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associated increase in IL-6.  At the dose and time point tested, the IL-6 antibody did block 
the increase in IL-6.  The last set of experiments were planned to evaluate the extent to which 
prior administration of anti-IL-6 antibody might mediate infected-associated changes in 
blood glucose, insulin, or body weight.  Anti-IL-6 antibody or irrelevant antibody was 
administered prior to and/or during infection.  Changes in blood glucose, insulin, IL-6, body 
weight, food and water intake were measured.     
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RESULTS 
 
High Serum IL-6 Level with Infection   
Mice were infected with of 50μl of influenza A/PR/8/34 at titer of 512 HAU, and IL-
6 was measured at days 1-5 post infection (n=4 mice per day). A statistically significant 
increase in serum IL-6 was found at day 2 (p=.001), day 3 (p= 0.03) and day 5 (p=0.01) 
compared to the control group inoculated with 50ul saline (Fig. 3). At a higher dose of virus 
(50 μl of 1024 HAU),   IL-6 was also found to be elevated significantly at day 1 (p= 0.03), 
day 2 (p<0.01), day 5 (p=0.01) and day 6 (p=0.03) post infection compared to day 0 (non-
infected group) (Fig. 4).   
 
Changes in Blood Glucose Level Post Infection 
In the first set of experiments, 50 μl of A/PR/8/34 influenza virus at a titer of 512 
HAU was administered and mice were euthanized day 1-5 post-infection.  Four different 
mice were euthanized each day.  The results of a one-way ANOVA showed that on day 5 
post infection, the decrease in blood glucose compared to pre-infection was different than the 
day to day change in blood glucose of non-infected mice (p=0.052) (Fig. 5).  However, days 
1-4 were not significantly different.  In the second set of experiments, a higher dose of virus 
was used (50 μl of 1024 HAU titer).  The same mice were used to measure blood glucose on 
days 1, 3, and 5 post-infection (n=8) (Fig. 6), and a different set of mice were used to 
measure glucose on days 2, 4, and 6, post-infection (n=8) (Fig. 7).  Change in blood glucose 
over time was compared to non infected mice (mixed ANOVA treatment X time).  The 
results showed a significant treatment by time interaction for mice assessed on days 1, 3, 5 
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post infection (p=0.001) and for mice assessed days 2, 4, 6 (p=0.003) (Figs. 6 & 7).  Upon 
post-test analysis (ANOVA comparison for each day), a significant decrease in blood glucose 
was found on days 2, 4, 5, and 6 post-infection, as compared to day to day variability in 
blood glucose of non-infected mice.  In Table 1, the change in blood glucose during infection 
was compared between mice infected with the viral titer of 512 HAU with mice infected with 
the titer of 1024 HAU.  With this day by day comparison of change in blood glucose, it was 
apparent that the higher dose of virus resulted in a greater decrease of blood glucose 
throughout the infection.  
 
Insulin Level in Response to Infection  
 The same mice that were used to assess IL-6 in serum were also used to measure 
insulin at several time points post-infection.  At the lower dose of virus (50 μl of 512 HAU), 
mice were euthanized day 1-5 post-infection (n=4 per day).  No significant differences were 
found in insulin during infection (Fig. 8). In contrast, at the higher dose of virus (50 μl 1024 
HAU), a significant increase in insulin was observed at day 1 post-infection p= 0.05. At day 
3 and 4 there was a trend towards lower insulin levels than in  non-infected, p=.06 for day 3, 
p= .08 for day 4 and on day 5, insulin was significantly lower than in non-infected mice at 
p=0.03 (Fig. 9).  The table below (Table 2) compares the insulin response to the two doses of 
virus.  It appears that the higher dose of virus affects insulin level to a greater extent.  
 
 
Body Weight, Water Intake, and Food Intake Changes with Infection 
Body weight and food intake were measured in the mice that were infected with 50 μl 
of the 1024 HAU titer A/PR/8/34 influenza virus.  A significant main effect of treatment 
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(p<0.001) (infection compared to non-infected) and a significant treatment by time 
interaction were observed.  On days 2, 3, 4, and 5, body weight of infected mice was 
significantly lower than non-infected (Fig. 10).  Food intake followed a similar pattern with a 
significant treatment effect (p<0.001) and a trend to a treatment by time interaction.  Food 
intake of infected mice was significantly lower than non-infected mice at day 2, 3, 4, and 5 
post-infection (Fig. 11).  Water intake did not differ between non-infected and infected mice 
(data not shown)  
 
Effect of Anti-IL-6 Ab Administration in Vivo on Infection-Associated Change in Blood 
Glucose 
Blood glucose was measured pre-infection and then at day 3 and 5 post-infection in 
mice treated with one of the following treatments, anti-IL-6 antibody, anti rat IG1κ isotype 
immunoglobulin, or saline in non-infected mice.  A significant main effect of treatment 
(p=0.001) and a treatment by time interaction (p=0.057) were found suggesting that the 
groups did not respond similarly over time.  A follow-up one-way-ANOVA for glucose 
measured each day separately showed no difference between the groups at pre-infection.  
However at day 3 post-infection, a significant effect of treatment was observed (p<0.001) 
such that both infected groups had a significant decrease in blood glucose compared to non-
infected mice, but the anti-IL-6 antibody treated mice were not different than the mice treated 
with irrelevant antibody.  At day 5 post-infection when the drop in blood glucose was 
typically more pronounced, a significant effect of infection was found (p=0.01).  However, 
the decrease in blood glucose was significantly different in mice receiving the irrelevant 
antibody when compared to non-infected (p=0.003), but NOT different between anti-IL-6 
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antibody-treated mice and non infected mice.  This finding suggests that the administration of 
IL-6 antibody may attenuate the drop in blood glucose at day 5 post-infection (Fig. 12) 
(although it should be noted that this was not a consistent effect across all of the mice). 
 
Effect on Anti-IL-6 Ab Administration in Vivo on Infection-Associated Change in 
Insulin  
 Five mice per group received the anti-IL-6 antibody treatment or the irrelevant 
antibody treatment whereas 22 mice per group served as non-infected controls (pooled 
experiments with all non-infected mice).   At days, 1, 2, and 5 post-infection insulin was 
measured.  At day 2 post-infection, insulin levels tended to decrease as previously observed 
(irrelevant antibody treated mice as compared to non-infected, although this did not meet 
statistical significant). However, the anti-IL-6 treated mice at day 2 post-infection did not 
demonstrate a decline in insulin and instead, their insulin level was significantly greater than 
infected mice treated with irrelevant antibody (p=0.04, Fig 13).  At day 5 post-infection, the 
infected mice tended to show a reduction in insulin (p=0.057) as compared to non-infected 
mice.  However, there was no difference between anti-IL-6 Ab-treated mice and irrelevant 
antibody-treated mice suggesting that IL-6 does not mediate the drop in insulin at day 5 post-
infection.  
 
Effect on Anti-IL-6 Ab Administration in Vivo on Infection-Associated Change in Body 
Weight and Food/Water Intake 
Although infection was associated with a significant drop in body weight at days 2-5 
post-infection (p<0.01) and food intake at days 1-4 post infection (p<0.015),  there was no 
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difference between mice receiving IL-6 antibody as compared to irrelevant antibody 
suggesting that IL-6 does not mediate changes in infection-associated weight loss or food 
intake (Fig. 14, 15).  Water intake did not change with infection and there were no 
differences between all three treatment groups with respect to water treatment (data not 
shown). 
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DISCUSSION 
 
Overall Summary of Findings 
The present study was designed to investigate the effect of infection-associated 
increases in serum IL-6 on glucose and insulin levels.  The change in glucose and insulin 
taken together was used to predict insulin sensitivity (although insulin sensitivity at the tissue 
was not measured in this study).  The results showed an elevation of serum IL-6 during 
infection and a decline in glucose level that reached statistical significance at day 5-6 post-
infection.  In contrast, insulin was significantly increased in response to infection on day 1 
post-infection, but decreased on days 3, 4, and 5 post-infection. With administration of anti-
IL-6 antibodies, the infection-associated decline in insulin as seen in previous experiments 
appeared to be prevented by administration of anti-IL-6 antibody only on day 2 post-
infection.  Also, the infection-associated decline in blood glucose at day 5 post-infection was 
attenuated in anti-IL-6 treated mice as compared to infected mice that received the irrelevant 
antibody. These findings support a role for IL-6 as a mediator of the infection-associated 
change in blood glucose and insulin levels.  With infection there was a tendency to decrease 
insulin and glucose levels started at day 2 and that decrease became more pronounced at day 
5 post-infection. These findings suggest that during infection there may be an increase in 
insulin sensitivity that predispose to the decline in glucose level at day 5. Whether infection-
induced IL-6 release is the mediator in insulin sensitivity is not determined yet.     
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Blood Glucose Changes in Association with Infection 
A change in blood glucose level is well documented during infection and therefore 
our results are consistent with other studies.  However the direction of the infection-
associated change in blood glucose (hyperglycemia vs. hypoglycemia) is variable. Patients 
infected with either bacterial or viral organisms may be hypoglycemic or hyperglycemic 
during infection (Ronan et al., 1997; Jaward et al., 1995, Yang et al., 2006, Andersen al., 
2004; Miller et al., 1980)).   It is not clear whether the type of infectious agent predicts hypo- 
or hyperglycemia, however the existing data with respect to this question are limited and it is 
not possible to draw a conclusion at this point. 
Also the mechanism(s) responsible for the changes in blood glucose is not well 
understood. In an attempt to study the mechanism(s) that may lead to glucose changes with 
infection, we have studied influenza infection in mice.  Evidence from other studies suggests 
that respiratory infection may precipitate the acute elevation of blood glucose in a diabetic 
person (Thomas et al., 1993), or could be associated with persistent glucose elevation after 3 
months of the onset of infection (Wasmuth et al., 2000). Also, hypoglycemia is associated 
with influenza virus infection, and laboratory findings in influenza associated-encephalitis 
patients infected with either influenza A and B virus revealed glucose level < 60mg/dl 
(Tsuneo et al., 2002). Therefore, we have studied influenza infection in a mouse model to 
better understand how infection might affect glucose and insulin levels. Previous attempts to 
better understand the relationship between bacterial infection and glucose were performed by 
using LPS injection (s.c. or i.p.) in experimental mice (Oguri et al., 2002). This study showed 
a decrease in glucose level with LPS injection in a dose dependant manner. There was also 
another study that showed influenza B virus injection in mice led to inhibition of the 
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mitochondrial phase of gluconeogenesis and decreased glucose level (Davis et al., 1993). To 
our knowledge, the potential role of cytokines as mediators of infection-related changes in 
glucose and/or insulin has not been evaluated.  Therefore, the experiments in our study were 
designed to test whether the cytokine IL-6 mediates changes in blood glucose and/or insulin 
during influenza infection.   
Our results showed that mice infected with influenza A/PR/8/34 at a dose of 50 μl of 
512 HAU showed a significant drop in blood glucose particularly at day 5, and that drop was 
more prominent with a greater dose of virus.  Although there was a decline in food intake 
during infection that could potentially cause a decrease in blood glucose, the time course of 
decreased blood glucose did not correspond directly with food intake.  Food intake is 
typically decreased on days 2-4 of infection, and begins to return to normal around day 5-6 
post-infection. Therefore, there may be other mechanisms responsible for the decline in 
glucose.  
 
IL-6 Increased with Infection 
It is possible that inflammatory cytokines produced during infection may regulate 
glucose homeostasis. Findings from other studies have shown that IL-6 increased with 
influenza infection in both vitro and vivo experiments (Seo at al., 2004; Chan et al., 2005; 
Conn et al., 1995). The increase in serum IL-6 was correlated with severity of illness in 
human subjects (Tsuneo et al., 2002; Kaiser et al., 2001). Our results are consistent with 
these other studies; we have observed a significant elevation of serum IL-6 with both low and 
high doses of infection. However, with a higher infectious dose (50 μl of 1024 HAU) we did 
not observe a greater level in serum IL-6 level as compared to the lower infectious dose (512 
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HAU). This may be due to the fact that the standard curve used to determine the level of 
serum IL-6 with the lower infectious dose was not within the typical range that is usually 
observed using the ELISA kit from BD Biosciences.  Therefore, it was not possible to 
directly compare absolute level of IL-6 between the two experiments using different doses of 
virus.  However, in both experiments IL-6 was significantly increased on day 2 and day 5 
post-infection. Also, our data showed that with the high virus dose the significant increase in 
IL-6 started earlier at day 1 post-infection as compared to day 2 with lower infectious dose.  
 
Correlation between IL-6 and Glucose / Insulin during Infection  
The data from our experiments indicated that the decline in glucose level was very 
prominent particularly at day 5-6 post-infection (at the same time in which serum IL-6 was 
elevated).  However, although IL-6 was increased at days 1-2 post-infection, there was no 
change in glucose.  That may suggest that early onset and increasing length of time in which 
circulating IL-6 is elevated is an important factor in predicting the impact of IL-6 on blood 
glucose during infection.  Perhaps a longer duration of exposure to elevated IL-6 (i.e. several 
days rather than 24-48 hrs) is necessary before an effect on blood glucose is found.    
It is possible that changes in insulin sensitivity result in altered blood glucose found at 
day 5-6 post-infection.   In support of this possibility, IL-6 has been found to play a role in 
altering insulin sensitivity and subsequent changes in glucose.  An in vitro study showed that 
3T3-L1 adipocytes treated with recombinant murine IL-6 for 5 hrs increased glucose 
transport by 20% (Stouthard et al., 1996). Also it has been shown that IL-6 infusion enhances 
insulin stimulated glucose disposal in human during hyperinsulinemic-euglycemic clamp 
(Carey et al., 2006). Therefore, IL-6 may be associated with an increase in insulin sensitivity 
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during infection. The increase in insulin sensitivity and enhancement of glucose uptake may 
be responsible for the decrease in glucose level found in our data at day 5-6 post-infection.  
Our results may have supported this possibility, given that we found a significant increase in 
serum IL-6 and tendency to decrease insulin level over time during infection with a 
significant drop at day 5 post-infection.  This decline in insulin level was also matched with a 
decrease in glucose and became statistically significant at day 5 and 6 post-infection. This 
suggested that IL-6 may influence blood glucose level during infection via enhancement of 
insulin sensitivity and glucose uptake.  In our experiments when anti-IL-6 antibody was 
administered, at day 5 post-infection, there was no effect of the antibody on insulin level, but 
the glucose level increased in antibody-treated mice.  With no effect of IL-6 on insulin, and 
blockade of IL-6 resulting in increased glucose, these findings suggested that acute increases 
in IL-6 might act to reduce blood glucose (or increase insulin sensitivity at day 5 post-
infection).  Given that serum IL-6 was increased for several days during infection and the 
significant decline in glucose and insulin was obvious later with infection, it is possible that 
prolonged exposure to IL-6 may be important to sensitize tissues to insulin and enhance 
glucose uptake which was predicted by decline in glucose level.  Also important to consider 
is that the IL-6 antibody appeared to prevent the decline in insulin that occurred early during 
infection (day 2), but had no effect on glucose on day 3.  This might suggest that early during 
infection (within hours), IL-6 acts to reduce insulin which is accompanied by a drop in blood 
glucose.   
 A possible mechanism by which IL-6 exerts its effect on the day5 decrease in blood 
glucose is through phosphorylation of tyrosine residue of IRS-1. IRS-1 phosphorylation will 
lead to PI3K activation as shown in Fig 1 (Carey et al 2004).  Activation of PI3K can lead to 
   
 
32
increase GlutT4 movements from the internal membrane vesicle to plasma membrane and 
increase glucose uptake resulting in a decline in blood glucose level.  
 
Other Factors that may Mediate Infection-Associated Decrease of Blood Glucose 
Other factors may be involved in the decrease of glucose level during infection. One 
study has shown a decrease in glucagon level during acute and convalescence periods in 
patient infected with either bacterial or viral pathogens (Sammalkorpi et al., 1989).  The 
decrease in glucagon level may be responsible for the decrease in glucose level in our 
experiments. Also inhibition of gluconeogenesis could be a possible cause in decreasing 
glucose level during infection as well. It was found that influenza B injection in mice model 
led to inhibition of the mitochondrial phase of gluconeogenesis and the pyruvate carboxylase, 
the main key enzyme in gluconeogenesis was largely displaced into the cytosol of 
hepatocytes (Davis et al., 1993).  Therefore, it is possible that IL-6 in combination with 
changes of other hormones that affect blood glucose level could be responsible for the 
hypoglycemic effect found in the infected mice. The results of our study suggested that IL-6 
mediates the hypoglycemic response observed at day 5-6 post-infection.  However, it is 
possible that IL-6 altered glucose by a direct effect on tissue insulin sensitivity as discussed 
earlier, or that IL-6 acted by altering other hormones that affect blood glucose.   
 Previous studies showed that both IL-1 alpha and IL-1 beta contribute to 
hypoglycemic effect in mice (Oguri et al., 2002; Endo et al., 1991). Therefore, it is also 
possible that IL-6 may also act on other cytokines and promote their release. IL-6 is known 
to induce acute phase protein including pro-inflammatory cytokine IL-1 (Janeway et al., 
2001). IL-1 subsequently could alter glucose homeostasis.  Therefore, other cytokines such 
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as IL-1 that are released in response to IL-6 may in fact be the cytokine that is directly 
responsible for alterations of blood insulin and glucose.  It is also possible that multiple 
cytokines acting together are involved in mediating glucose and insulin.  Further studies 
using knockout mice or antibodies against multiple cytokines would be required to establish 
whether multiple cytokines are involved.  
 
IL-6 and Insulin Resistance Early with Infection            
          It was documented that direct injection of LPS in human led to immediate elevation in 
IL-6, insulin and glucose levels in the first 24 after injection (Andersen et al., 2007). That 
may indicate that there may be a state of increased insulin resistance due to IL-6 elevation 
with LPS injection.  Our results in an infection model were somewhat consistent with the 
studies using LPS.  Our data showed a higher infectious dose resulted in an early significant 
elevation of IL-6 and insulin level at day 1 post infection.  This may suggest that there may 
be a state of increased insulin resistance early with infection (up to 24 hours post-infection). 
Although some of our findings at later time points during infection (day 5-6) suggest Based 
there is an increase in insulin sensitivity later with infection, it is possible that both insulin 
resistance and insulin sensitivity could occur at different time points during infection. The 
increase in insulin resistance may be occurring early with infection followed by gradual 
increase in insulin sensitivity. Perhaps a short-term exposure (hours) to IL-6 results in insulin 
resistance whereas prolonged exposure to IL-6 results in greater insulin sensitivity.  At the 
cellular level, different signaling pathways might be influenced by short-term versus longer 
term exposure to IL-6. Another possibility is that different tissues are affected by different 
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lengths of time of exposure to IL-6.  For example, there may be a partial increase in insulin 
resistance on hepatocytes early with infection followed by increase in glucose disposal and 
body uptake at the periphery (adipose and muscle). However, further experiments are 
required to determine which of these possibilities may be correct.  In general, it was apparent 
that with either low or high virus dose there was a significant decline in glucose level that 
might be related to insulin sensitivity.   
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CONCLUSION 
 
We have tested the role of IL-6 during infection on glucose and insulin via 
administration of IL-6 neutralizing antibodies.  Based on the decrease in glucose and insulin 
levels and the potential increase in insulin sensitivity later (at day 5 post-infection), we 
hypothesized that IL-6 antibody treatment would block the increased insulin sensitivity 
resulting in either an increase in insulin level or attenuation in the decline of glucose level.  
The results showed that anti-IL6 antibodies treatment did attenuate the drop of glucose level 
associated with influenza infection in mice (at day 5 post-infection). Also, there were no 
effects of anti-IL-6 antibody treatment on body weight or food intake.  Those results taken 
together suggest a potential role of IL-6 exists with respect to the infection-mediated 
decrease of glucose (day 5-6 p.i.) (unrelated to the consumed food amount). Anti-IL-6 
antibody treatment did also appear to prevent an infection-associated decrease in insulin at 
day 2 post-infection compared to infected group with irrelevant antibodies. This may indicate 
that IL-6 have a role in insulin homeostasis with infection.   Taken together, these findings 
suggest that IL-6 acts to mediate glucose and insulin level during infection. IL-6 may 
increase insulin sensitivity during infection. However we have to determine whether IL-6 has 
a direct effect on tissue insulin sensitivity and subsequent blood glucose level or whether IL-
6 acts on other cytokines or hormones which in turn mediate blood glucose.  
 
 
 
 
   
 
36
REFERENCES 
 
Andersen SK, Gjedsted J, Christiansen C, Tonnesen E. The roles of insulin and 
hyperglycemia in sepsis pathogenesis. 2004. J Leukoc Biol. 75(3):413-21.  
 
Anderson PD, Mehta NN, Wolfe ML, Hinkle CC, Pruscino L, Comiskey LL, Tabita-
Martinez J, Sellers KF, Rickels MR, Ahima RS, Reilly MP. Innate immunity modulates 
adipokines in humans. 2007. J Clin Endocrinol Metab. Jun;92(6):2272-9. 
 
Arsand E, Arsand EWalseth OA, Andersson N, Fernando R, Granberg O, Bellika JG,  
     Hartvigsen G. Using blood glucose data as an indicator for epidemic disease outbreaks.   
     2005. Stud Health Technol Inform.116:217-22. 
 
Basoglu OK, Bacakoglu F, Cok G, Sayiner A, Ates M. The oral glucose tolerance test in 
patients with respiratory infections. 1999. Monaldi Arch Chest. 54(4):307-10.  
 
Bastard JP, Maachi M, Van Nhieu JT, Jardel C, Bruckert E, Grimaldi A, Robert JJ, Capeau J, 
Hainque B. Adipose tissue IL-6 content correlates with resistance to insulin activation of 
glucose uptake both in vivo and in vitro. 2002. J Clin Endocrinol Metab. 87(5):2084-9. 
 
Bouter KP, Diepersloot RJ, van Romunde LK, Uitslager R, Masurel N, Hoekstra JB, 
Erkelens DW. Effect of epidemic influenza on ketoacidosis, pneumonia and death in 
diabetes mellitus: a hospital register survey of 1976-1979 in The Netherlands. 1991. 
Diabetes Res Clin Pract. 12(1):61-8. 
 
Carey AL, Steinberg GR, Macaulay SL, Thomas WG, Holmes AG, Ramm G, Prelovsek O, 
Hohnen-Behrens C, Watt MJ, James DE, Kemp BE, Pedersen BK, Febbraio MA. 
Interleukin-6 increases insulin-stimulated glucose disposal in humans and glucose uptake 
and fatty acid oxidation in vitro via AMP-activated protein kinase. 2006. Diabetes. 
Oct;55(10):2688-97. 
 
Carey AL, Febbraio MA. Interleukin-6 and insulin sensitivity: friend of foe? 2004. 
Diabetologia 47:1135-1142 
 
Chan MC, Cheung CY, Chui WH, Tsao SW, Nicholls JM, Chan YO, Chan RW, Long HT, 
Poon LL, Guan Y, Peiris JS. Proinflammatory cytokine responses induced by influenza A 
(H5N1) viruses in primary human alveolar and bronchial epithelial cells. 2005. Respir 
Res. Nov 6:135. 
 
Cheung CY, Poon LL, Lau AS, Luk W, Lau YL, Shortridge KF, Gordon S, Guan Y, Peiris 
JS. Induction of proinflammatory cytokines in human macrophages by influenza A 
(H5N1) viruses: a mechanism for the unusual severity of human disease?. 2002. Lancet. 
360(9348):1831-7. 
  
   
 
37
Conn CA, McClellan JL, Maassab HF, Smitka CW, Majde JA, Kluger MJ. Cytokines and the 
acute phase response to influenza virus in mice. 1995. Am J Physiol. 268(1 Pt 2):R78-84. 
 
Davis LE, Woodfin BM, Tran TQ, Caskey LS, Wallace JM, Scremin OU, Blisard KS. The 
influenza B virus mouse model of Reye's syndrome: pathogenesis of the hypoglycaemia. 
1993. Int J Exp Pathol. Jun;74(3):251-8.  
 
Diepersloot RJ Diepersloot RJ, Bouter KP, Hoekstra JB. Influenza infection and diabetes 
mellitus. Case for annual vaccination. 1990. Diabetes Care. 13(8):876-82. 
 
Emanuelli B, Peraldi P, Filloux C, Chavey C, Freidinger K, Hilton DJ, Hotamisligil GS, Van 
Obberghen E. SOCS-3 inhibits insulin signaling and is up-regulated in response to tumor 
necrosis factor-alpha in the adipose tissue of obese mice. 2001. J Biol Chem. 
276(51):47944-9.  
 
Emanuelli B, Peraldi P, Filloux C, Sawka-Verhelle D, Hilton D, Van Obberghen E. SOCS-3 
is an insulin-induced negative regulator of insulin signaling. 2000. J Biol Chem. 
275(21):15985-91. 
 
Endo Y. Parallel relationship between the increase in serotonin in the liver and the 
hypoglycaemia induced in mice by interleukin-1 and tumour necrosis factor. 1991. 
Immunol Lett. 27(1):75-9. 
 
Engelich G, Wright DG, Hartshorn KL. Acquired Disorders of Phagocyte Function 
Complicating Medical and   Surgical Illnesses. 2001. Clin Infect Dis.33(12):2040-8. 
 
Enserink M. Influenza: girding for disaster. Looking the pandemic in the eye. 2004. Science. 
306(5695):392-4. 
 
Harnish MJ, Lange T, Dimitrov S, Born J, Fehm HL. Differential regulation of human blood 
glucose level by interleukin-2 and -6. 2005. Exp Clin Endocrinol Diabetes. 113:43-48.        
 
Haugaard SB, Andersen O, Volund A, Hansen BR, Iversen J, Andersen UB, Nielsen JO, 
Madsbad S. Beta-cell dysfunction and low insulin clearance in insulin-resistant human 
immunodeficiency virus (HIV)-infected patients with lipodystrophy. 2005. Clin 
Endocrinol.62(3):354-61. 
 
Heliovaara MK, Teppo AM, Karonen SL, Tuominen JA, Ebeling P. Plasma IL-6 
concentration is inversely related to insulin sensitivity, and acute-phase proteins associate 
with glucose and lipid metabolism in healthy subjects. 2005. Diabetes Obes Metab. 
7(6):729-36. 
 
Hiesmayr MJ. Hyperglycemia and outcome after myocardial infarction and cardiac surgery: 
so what?. 2006. Semin Cardiothorac Vasc Anesth.  10 (3):220-3. 
   
 
38
 Hjelmesaeth J, Sagedal S, Hartmann A, Rollag H, Egeland T, Hagen M, Nordal KP, Jenssen 
T.  Asymptomatic cytomegalovirus infection is associated with increased    risk of new-
onset diabetes mellitus and impaired insulin release after renal transplantation. 2004. 
Diabetologia.47(9):1550-6.     
 
Holm C, Horbrand F, Mayr M, von Donnersmarck GH, Muhlbauer W. Acute hyperglycemia 
following thermal injury: friend or foe?. 2004. Resuscitation. 60 (1):71-7 
 
Horwitz MS, Ilic A, Fine C, Rodriguez E, Sarvetnick N. Coxsackievirus-mediated 
hyperglycemia is enhanced by reinfection and this occurs independent of T cells. 2003. 
Virology. Sep 30; 314(2):510-20 3. 
 
Hsieh YC, Wu TZ, Liu DP, Shao PL, Chang LY, Lu CY, Lee CY, Huang FY, Huang LM. 
Influenza pandemics: past, present and future. 2006. J Formos Med Assoc. 105(1):1-6. 
 
Hypo-Jeong Kim, et al: Differential effect of Interleukin-6 and -10 on Skeletal Muscle and     
       Liver Insulin Action In Vivo. 2004. Diabetes, 53: 1060-1067. 
 
Janeway CA, Travers P, Walport M, Shlomchik MJ. Immunobiology. 2001.  
 
Jawad F, Shera AS, Memon R, Ansari G. Glucose intolerance in pulmonary tuberculosis. 
1995. J Pak Med Assoc. 45(9):237-8.   
 
Kaiser L, Fritz RS, Straus SE, Gubareva L, Hayden FG.  Symptom pathogenesis during acute 
influenza: interleukin-6 and other cytokine responses. 2001. J Med Virol. 64(3):262-8. 
 
Klover PJ, Zimmers TA, Koniaris LG, Mooney RA. Chronic exposure to interleukin-6 
causes hepatic insulin resistance in mice. 2003. Diabetes. 52(11):2784-9. 
 
Kwon SY, Kim SS, Kwon OS, Kwon KA, Chung MG, Park DK, Kim YS, Koo YS,  Kim 
YK, Choi DJ, Kim JH. Prognostic significance of glycaemic control in patients with 
HBV and HCV-related cirrhosis and diabetes mellitus. 2005. Diabet Med. 22(11):1530-5. 
 
Li KS, Guan Y, Wang J, Smith GJ, Xu KM, Duan L, Rahardjo AP, Puthavathana P, 
Buranathai C, Nguyen TD, Estoepangestie AT, Chaisingh A, Auewarakul P, Long HT, 
Hanh NT, Webby RJ, Poon LL, Chen H, Shortridge KF, Yuen KY, Webster RG, Peiris 
JS. Genesis of a highly pathogenic and potentially pandemic H5N1 influenza virus in 
eastern Asia. 2004. Nature.430(6996):209-13. 
 
 Lipatov AS, Andreansky S, Webby RJ, Hulse DJ, Rehg JE, Krauss S, Perez DR, Doherty 
PC, Webster RG, Sangster MY. Pathogenesis of Hong Kong H5N1 influenza virus NS 
gene reassortants in mice: the role of cytokines and B- and T-cell responses. 2005. J Gen 
Virol. 86(Pt 4):1121-30. 
 
   
 
39
Metzger S, Nusair S, Planer D, Barash V, Pappo O, Shilyansky JChajek-Shaul T. Inhibition 
of hepatic gluconeogenesis and enhanced glucose uptake contribute to the development 
of hypoglycemia in mice bearing interleukin-1 beta secreting tumor. 2004. 
Endocrinology. 145(11):5150-6.  
 
Miller SI, Wallace RJ Jr, Musher DM, Septimus EJ, Kohl S, Baughn RE. Hypoglycemia as a 
manifestation of sepsis. 1980. Am J Med. 68(5):649-54. 
 
Morishima T, Togashi T, Yokota S, Okuno Y, Miyazaki C, Tashiro M, Okabe N,   
Collaborative Study Group on Influenza-Associated Encephalopathy in Japan. 
Encephalitis and encephalopathy associated with an influenza epidemic in Japan. 2002. 
Clin Infect Dis.35(5):512-7. 
 
Moutschen M. Alterations in natural immunity and risk of infection in patients with diabetes 
mellitus. 2005. Rev Med Liege.60(5-6):541-4. 
 
Mowla A, Karimi M, Afrasiabi A, De Sanctis V. Prevalence of diabetes mellitus and 
impaired glucose tolerance in beta-thalassemia patients with and without hepatitis C virus 
infection. 2004. Pediatr Endocrinol Rev.2  Suppl 2:282-4. 
 
Norhammar A,Tenerz A, Nilsson G, Hamsten A, Efendic S, Ryden L, Malmberg K. Glucose 
metabolism in patients with acute myocardial infarction and no previous   diagnosis of 
diabetes mellitus: a prospective study. 2002. Lancet. 359(9324):2140-4 
 
Oguri S, Motegi K, Iwakura Y, Endo Y. Primary role of interleukin- 1alpha and interleukin- 
1 beta in lipopolysaccharide-induces hypoglycemia in mice. 2002. Clin Diagn Lab 
Immunol. 9(6):1307-12. 
 
Orban JC, Deroche D, Ichai C. Septic shock: blood glucose regulation. 2006. Ann Fr Anesth 
Reanim. 25(3):275-9.  
 
Petersen EW, Carey AL, Sacchetti M, Steinberg GR, Macaulay SL, Febbraio MA,  Pedersen 
BK. Acute IL-6 treatment increases fatty acid turnover in elderly humans in vivo and in 
tissue culture in vitro. 2004. Am J Physiol Endocrinol Metab. Jan;288(1):E155-62. 
 
Reading PC, Allison J, Crouch EC, Anders EM. Increased susceptibility of diabetic mice to 
influenza virus infection: compromise of collectin-mediated host defense of the lung by 
glucose?. 1998. J Virol.72(8):6884-7. 
 
Ronan A, Azad AK, Rahman O, Phillips RE, Bennish ML.Hyperglycemia during childhood 
diarrhea. 1997. J Pediatr. 130(1):45-51. 
 
Rotter SV, Larsson BM, Johansson A, Holmäng A, Smith U. Short-term infusion of 
interleukin-6 does not induce insulin resistance in vivo or impair insulin signalling in rats. 
2004. Diabetologia. Nov; 47(11):1879-87.  
   
 
40
Rotter V, et al:  Interleukin-6 (IL-6) induces insulin resistance in 3T3-L1 adipocytes and is, 
like IL-8 and tumor necrosis factor-alpha, overexpressed in human fat cells from insulin-
resistant subjects. 2003. J Biol Chem. 278(46):45777-84.            
 
Sammalkorpi K. Glucose intolerance in acute infections. 1989. J Intern Med.  225(1):15-9. 
 
Segado Soriano A,Lopez Gonzalez-Cobos C, Granda Martin MJ, Villalba Garcia M, Gil 
Gonzalez J, Farfan Sedano A.Infectious pathology in diabetic patients cared for in an 
emergency department. 1999. An Med Interna. 16 (1):1-2. 
 
Senn JJ, Klover PJ, Nowak IA, Mooney RA. Interleukin-6 induces cellular insulin resistance 
in hepatocytes. 2002 . Diabetes. 51(12):3391-9. 
 
Seo SH, Webby R, Webster RG. No apoptotic deaths and different levels of inductions of 
inflammatory cytokines in alveolar macrophages infected with influenza viruses. 2004. 
Virology. 329(2):270-9. 
 
Simon W. Coppack Pro-inflammatory cytokines and adipose tissue. 2001. Proceedings of the 
Nutrition Society. 60: 349-356. 
 
Spinetti N, Zavala-Spinetti L, Hempe J, Correa H, Begue RE. Effect of long-term 
Helicobacter felis infection in a mouse model of streptozotocin-induced diabetes. 2005. 
Helicobacter.10(6):586-91. 
 
Starnes HF Jr, Pearce MK, Tewari A, Yim JH, Zou JC, Abrams JS. Anti-IL-6 monoclonal 
antibodies protect against lethal Escherichia coli infection and lethal tumor necrosis 
factor-alpha challenge in mice. 1990.  J Immunol. Dec 15;145(12):4185-91. 
 
Stouthard JM, Oude Elferink RP, Sauerwein HP. Interleukin-6 enhances glucose transport in 
3T3-L1 adipocytes. 1996. Biochem Biophys Res Commun. Mar 18;220(2):241-5. 
 
Thomas E.A, J.Claude Bennett, Charles C.J., Fred Plum, Lloyd H. Smith. Cecil Essential of 
Medicine.1993.Third edition  
 
Trotti R, et al: Adipose tissue and cytokines. 2001. Minerva Gastroenterol Dietol. 47(4):205-
207. 
 
Tsigos C, Papanicolaou DA, Kyrou I, Defensor R, Mitsiadis CS, Chrousos GP. Dose 
dependent effects of recombinant human interleukin-6 on glucose regulation. 1997. J 
Clin Endocrinol Metab. 82(12):4167-70. 
 
Wallenius V, Wallenius K, Ahrén B, Rudling M, Carlsten H, Dickson SL, Ohlsson   C, 
Jansson JO. Interleukin-6-deficient mice develop mature-onset obesity. 2002. Nat Med.  
Jan;8(1):75-9. 
 
   
 
41
Warren E., Ernest J. Medical microbiology and Immunology. 1994. Third edition. 
 
Wasmuth HE, Hess G, Viergutz C, Henrichs HR, Martin S, Kolb H. Non-specific viral 
infections as possible synchronising events of the manifestation of type 1 diabetes. 2000. 
Diabetes Metab Res Rev. 16(3):177-8. 
 
Whitcomb BW, Pradhan EK, Pittas AG, Roghmann MC, Perencevich EN. Impact of 
admission hyperglycemia on hospital mortality in various intensive care unit populations. 
2005. Crit Care Med. 33(12):2772-7. 
 
Yang JK, Feng Y, Yuan MY, Yuan SY, Fu HJ, Wu BY, Sun GZ, Yang GR, Zhang XL, 
Wang L, Xu X, Xu XP, Chan JC.  Plasma glucose levels and diabetes are independent 
predictors for mortality and morbidity in patients with SARS. 2006. Diabet Med. 
23(6):623-8. 
 
Yki-Jarvinen H, Sammalkorpi K, Koivisto VA, Nikkila EA. Severity, duration, and 
mechanisms of insulin resistance during acute infections. 1989. J Clin Endocrinol Metab. 
69(2):317-23. 
 
Yu WK, Li WQ, Li N, Li JS.  Influence of acute hyperglycemia in human sepsis on 
inflammatory cytokine and counterregulatory hormone concentrations. 2003. World J 
Gastroenterol. 9(8):1824-7. 
 
 
 
 
 
 
 
 
 
   
 
42
TABLES 
 
 
 
Table 1: Changes in blood glucose (post-pre-infection). 
Units = mg/dl mean ± S.E. 
Virus 
dose 
Non 
infected  
Day 1 Day 2 Day 3 Day 4 Day 5 Day 6 
512HAU 0.0 ± 9.1 5.0± 17.1 1.25 ± 9.9 3.0 ±5.8 12.5± 4.1  -30.2 ±10.4  
(p=0.052)* 
 
 
1024HAU 9.0±7.2 5.0 ±9.3  -21.7 ± 2.0 
(p=0.005)* 
-3.7± 3.5  
(p=0.111)+ 
-26.3± 6.3  
(p=0.013)* 
-29.5± 6.7  
(p=0.008)* 
-60.5± 7.2  
(p=0.001)* 
  
 
 
Table 2: Change in insulin level with infection. 
Virus dose  Non 
infected  
Day 1 Day 2 Day 3 Day 4 Day 5 
512 HAU 0.82 ± 0.42 0.41 ± 0.29  0.52 ± 0.27 0.36 ± 0.18  0.52 ± 0.15 0.33 ± 0.21 
1024 HAU 0.51 ± 0.18 2.10 ± 0.57 
(p=0.04)* 
1.18 ± 0.61 0.21 ± 0.18 0.30 ± 0.14  0.11 ±  0.08  
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 FIGURES 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1: Hypothesized role for IL-6 in the etiology of insulin sensitivity. IL-6 may     
               phosphorylate IRS-1 on tyrosine residue and enhance insulin action and sensitivity.  
               However, IL-6 may activate suppressors of cytokine signaling through Jak/Stat  
               pathway to inhibit tyrosine phosphorylation of IRS-1. This will lead to impair   
               insulin signaling and increase insulin resistance. In chronic elevation of IL-6 may  
               phosphorylate Akt, which in turn lead to phosphorylation of serine instead of  
               tyrosine residue on IRS-1 and inhibit insulin action, (Pictorial is redrawn from  
    Diabetologia 2004).  
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Figure 2: Intra-peritoneal injection of 100 μg/100μl of anti-IL6 neutralizing antibodies in   
                mice infected with influenza A virus at a dose of 50 μl at 1024 HAU/0.05 ml.  
                Successfully blocking serum IL-6 at day 1 post-infection with tendency to    
                decrease at day 2 in the serum compared to infected mice injected with 100 μl     
                saline. 
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Figure 3: Infection with influenza A virus at titer of 512 HAU/0.05ml. Significant increase in 
serum IL-6 at day 2, 3 and 5 post-infection compared to non-infected 
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Figure 4: Infection with influenza A at titer of 1024 HAU/0.05ml. A statistically significant 
increase in serum IL-6 at days 1, 2, 5 and 6 post-infection compared to day 0 (non-
infected) p< 0.05.  
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Figure 5: Infection with influenza A virus at titer of 512 HAU/0.05ml. A significant decline 
in glucose level was observed at day 5 post-infection compared to pre-infection 
level.   
 
   
 
48
Glucose level with 1024 HAU/0.05ml 
           days 1,3 and 5 PI
days 
day 0 day 1 day 3 day 5
m
g/
dl
70
80
90
100
110
120
130
*
n=8
 
 
 
 
Figure 6: Infection with influenza A virus at titer of 1024 HAU/0.05ml and blood glucose 
was measured at days 0, 1, 3 and 5 post-infection in the same mice. A significant 
decline in glucose level at day 5 post infection was found compared to pre-
infection.    
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Figure 7: Infection with influenza A virus at titer of 1024 HAU/0.05ml, and blood glucose 
was measured at days 0, 2, 4 and 6 post-infection in the same mice group. A 
significant decline in glucose level was found at day 2, 4 and 6 post-infection 
compared to pre-infection.    
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Figure 8: Infection with influenza A virus at titer of 512 HAU/0.05ml. No significant                  
changes in insulin level were found as compared to the non infected group.  
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Figure 9: Infection with influenza A virus at titer of 1024 HAU/0.05ml.  A significant 
increase in insulin level at day 1 post infection was observed as compared to day 0 
non infected group. There is a trend towards lower insulin levels at days 3 and 4 
post-infection with a significant decrease of insulin level at day 5 post-infection 
p=0.03.  
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Figure 10: Infection with influenza A virus at titer of 1024 HAU/0.05ml. A significant 
weight loss at day 2, 3, 4, 5 and 6 post-infection was found as compared to non-
infected mice. 
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Figure 11: Infection with influenza A virus at titer of 1024 HAU/0.05ml. The amount of food 
intake was calculated by subtracting the total amount of food present in the mouse 
cage from the total amount of food on the previous day. A significant reduction in 
food intake at day 2, 3, and 4 post-infection was found as compared to the non 
infected group.  
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Figure 12: Intra-peritoneal injection of IL-antibody treatment in mice infected with influenza  
                  A virus at a dose of 50 μl at 1024 HAU/0.05 ml.  At day 3, glucose level in IL-6  
                  Ab and control Ab were significantly lower than non-infected, and at day 5 the  
                  IL-6 Ab attenuated the drop in blood glucose such that glucose level of control   
                  Ab-treated mice was significantly lower than non-infected mice.  
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Figure 13: Insulin level in mice treated with anti-IL-6 Ab, control Ab, or non-infected mice 
(infected with 50 μl of 1024 HAU/0.05 ml). At day 2, insulin level in IL-6 treated 
group was significantly greater than insulin level in infected group with control 
antibody p=0.04.   
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Figure 14: Body weight changes in mice treated with Anti-IL-6 Ab, control Ab or non-
infected (infected with 50 μl of 1024 HAU/0.05 ml).  There were no significant 
differences in body weight loss between anti-IL-6 Ab-treated infected mice as 
compared to infected mice treated with irrelevant antibodies.  However body weight 
of both infected groups was lower than non-infected at days 1,2,3,4, and 5 post-
infection.  
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Figure 15: Food intake changes in antibodies treated groups. There was no difference in food 
intake between mice treated with anti-IL-6 Ab as compared to control Ab, however 
both infected groups of mice had significantly lower food intake on days 2-5 post-
infection as compared to non-infected mice (infected with 50 μl of 1024 HAU/0.05 
ml). 
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